Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.
1 other identifier
observational
N/A
0 countries
N/A
Brief Summary
The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 17, 2007
CompletedFirst Posted
Study publicly available on registry
April 20, 2007
CompletedStudy Start
First participant enrolled
May 1, 2007
CompletedApril 22, 2011
April 1, 2011
April 17, 2007
April 21, 2011
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Male or female patient of age 18 years or older.
- Patient with intraabdominal/hepatobiliary infection.?
You may not qualify if:
- Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
April 17, 2007
First Posted
April 20, 2007
Study Start
May 1, 2007
Last Updated
April 22, 2011
Record last verified: 2011-04